0001295947-26-000016
SEC filingFY2026 delivered resilient profitability and cash generation despite a 4.3% revenue decline driven by supply disruptions, as strong gross margins and operating leverage offset expense pressures while maintaining low capital intensity.
Prestige Consumer Healthcare faced revenue challenges in FY2026, with net sales declining 4.3% to $1.1 billion from $1.1 billion in FY2025. This headwind stemmed from ongoing supply constraints, particularly affecting sterile eye care products like Clear Eyes, which limited availability, product mix, and ability to meet demand. These disruptions have persisted and are expected to continue impacting net revenues and customer service levels amid volatile economic conditions pressuring prices and supply chains.
Despite lower topline, gross profit of $595.6 million yielded a stable 54.7% margin, down modestly from prior year levels. This resilience reflects the benefits of the company's asset-light model, outsourcing manufacturing to leverage third-party core competencies while maintaining a highly variable cost structure, low overhead, and minimal working capital needs. Strategic shifts, including the Pillar5 acquisition for sterile ophthalmic capacity, introduced some margin pressure through related costs but positioned the company for improved supply security.
Operating income fell 8.1% to $309.4 million, representing a 28.4% margin on revenue. The decline was driven by higher general and administrative expenses, primarily from increased compensation-related costs, acquisition-related expenses, and an elevated allowance for doubtful accounts tied to one specific customer. These factors compressed profitability, though the company's disciplined approach to expenses helped preserve strong operating leverage.
Net income decreased 11.3% to $190.3 million, with diluted EPS at $3.91 versus $4.29 prior year. The higher effective tax rate compared to FY2025, due to a greater mix of U.S. earnings, further impacted bottom-line results. Notwithstanding earnings pressure, cash generation remained robust: net cash from operating activities increased to $257.6 million from $251.5 million, enabling free cash flow of $246.4 million after $11.2 million in capital expenditures—up slightly from $8.2 million but still reflecting minimal investment needs inherent to the outsourced model.